Articles tagged with Breast Cancer
A new study published in JNCI: Journal of the National Cancer Institute found that breast cancer screening costs increased substantially among older women between 2001 and 2009, despite unchanged detection rates of early-stage tumors. The study analyzed data from the SEER-Medicare linked database and found a significant increase in scr...
A new skin gel form of tamoxifen has been developed and tested on women with non-invasive breast cancer, reducing cancer cell growth while minimizing side effects. The gel application was found to be effective in reducing blood clot risk associated with oral tamoxifen, offering a safer treatment option.
A two-year study will examine the effects of cognitive behavioral and relaxation training on immune system functioning after surgery. Women who received these interventions reported reduced distress, improved mood, and enhanced emotional-well-being.
Researchers isolated breast cancer cells from patients' blood and expanded them in the lab, identifying new mutations and drug susceptibility. The study found a promising drug, Ganetspib, effective in killing tumor cells with specific genetic mutations.
Researchers at Massachusetts General Hospital developed a microchip-based device to capture and culture circulating tumor cells (CTCs) for genetic analysis and drug testing. The study found that cultured CTCs accurately reflect a tumor's genetic mutation over time, revealing new mutations and potential drug targets.
Researchers found that women with breast cancers involving the skin have widely varied survival rates, differing by tumor size and nodal involvement. They recommend adding a new staging category for tumors with skin involvement to accurately reflect a woman's chances of surviving her cancer.
A study of over 1 million patients in the UK found an association between high blood cholesterol and increased breast cancer risk. The researchers suggest that lowering cholesterol with statins may help prevent or treat breast cancer, warranting further investigation.
A study by Yale University researchers found that Medicare spending on breast cancer screening increased significantly between 2001 and 2009, despite no corresponding decrease in new breast cancer cases. The use of digital mammography technology, which is more expensive than standard film technology, contributed to the increase.
A 30-year follow-up study found no link between fertility drugs and breast, ovarian, and uterine cancers, except for extended use of clomiphene citrate. The study of 12,193 women treated for infertility showed a higher risk of invasive breast cancer with clomiphene use in 12 or more treatment cycles.
A recent study published in Nature Genetics has discovered a single gene that defines the difference between fast-growing, aggressive tumors and slow-growing, non-aggressive ones. The gene mutation GTF2l was found to be present in almost all indolent forms of thymoma, suggesting potential implications for treatment.
A study of adoptees found that genetics play a significant role in the development of these three types of cancer. The risk was 80% higher when an adoptee had at least one biological parent with the same cancer.
Researchers found that triple-negative breast cancer tumors rely on an antiviral pathway driving inflammation, which can be treated with JAK inhibitors. Patients missing both p53 and ARF genes may benefit from these anti-inflammatory drugs.
Researchers have found a consistent pattern of gene expression associated with tumor spreading in mice, which was also found in human oral cancer samples. A transcriptional signature predicting metastatic disease was identified with about 93% accuracy.
Researchers identified an epigenetic signature in blood samples from women with a BRCA1 mutation that increased cancer risk and lower survival rates. The same signature was found in women without the mutation who developed breast cancer, indicating it may predict breast cancer risk several years before diagnosis.
Researchers at Drexel University found a significant spike in Google searches for autism in April, with an average increase of 26 percent between March and April. The study analyzed web search trends from 2004 to 2014 and also found a long-term increasing trend for Asperger's disorder searches.
A study by Princeton University researchers found that the Metadherin gene, implicated in promoting breast cancer tumors, only stimulates growth when bound to its partner protein SND1. The research reveals that MTDH plays a role in both initial tumor growth and metastasis, but not normal cell growth or development.
Activation of estrogen receptor β (ERβ) has been shown to limit tumor cell growth in breast cancer. In mouse models, cancer cells with activated ERβ did not grow well. Conversely, breast cancer patients with activated ERβ in their tissue had increased disease-free survival rates.
Researchers discovered that a virus called AAV2 can kill triple-negative breast cancer cells and tumors in mice, with no adverse effects. The virus initiates apoptosis, or natural cell death, without affecting healthy cells, offering new possibilities for treatment of aggressive breast cancer.
A recent study published in JAMA found that 3D mammography significantly improves detection of invasive breast cancers, reducing call-back rates by 15%. This technology has shown promise in improving breast cancer screening outcomes, particularly for younger women and those with dense breast tissue.
The study found that adding tomosynthesis to mammography increased cancer detection rates by 27% and reduced false-positive results, while also decreasing unnecessary tests and biopsies. This technology has the potential to optimize patient outcomes from mammography screening.
A large retrospective study published in JAMA found that 3D mammography significantly increases detection of invasive cancers (41% increase) while reducing unnecessary recalls for false alarms. The technology also improves detection of all breast cancers by 29%.
A new imaging technique combining four approaches can distinguish between malignant and benign breast tumors with high accuracy, potentially avoiding unnecessary biopsies. The multiparameter PET-MRI method showed a 96% success rate in distinguishing malignant from benign tumors.
Researchers found that BPA increases breast cancer cell proliferation and diminishes the effect of treatments for inflammatory breast cancer cells. The study suggests a possible link between BPA exposure and treatment resistance in breast cancer patients.
A new study shows that even triple negative breast cancers with low androgen receptor expression can benefit from anti-androgen receptor therapy. The treatment, which targets the androgen receptor, was found to increase programmed cell death, inhibit growth, and increase necrosis in animal models.
Researchers discovered that the androgen receptor may play a crucial role in treating estrogen receptor-positive breast cancer. The study found that women with high levels of androgen receptors were more likely to experience cancer recurrence during tamoxifen treatment.
Researchers have developed a clinically relevant mouse model for squamous cell lung cancer, driven by the misregulation of genes sox2 and lkb1. The discovery uncovers new treatment strategies and provides insights into potential targeted therapies.
Researchers at Albert Einstein College of Medicine will study how breast cancer cells move and spread in the body. They aim to develop a test that predicts which breast cancer tumors will metastasize, based on the presence of a trio of cells called a tumor microenvironment of metastasis.
Research from the University of Texas MD Anderson Cancer Center found that African American women with early-stage invasive breast cancer were 12% less likely to receive axillary sentinel lymph node biopsy, a minimally invasive technique. The study also showed that those who received older, more invasive axillary lymph node dissection ...
Researchers identified racial disparities in the use of sentinel lymph node biopsy (SLNB) among black and white women with early-stage breast cancer. Black women were 12% less likely to undergo SLNB, contributing to higher risk for lymphedema compared to white patients.
A recent study by Dartmouth-Hitchcock Norris Cotton Cancer Center found that 22 out of 552 women had their tumor type incorrectly classified using conventional HER2 testing. The study confirmed the importance of accurate HER2 testing, as incorrect classification can have significant implications for treatment decisions.
A randomized trial found that telephone-based weight loss advice reduced breast cancer recurrence risk by lowering weight and inflammation. Postmenopausal women with breast cancer who received lifestyle coaching via phone achieved comparable sustained weight loss to in-person consultations.
A study of over 59,000 patients found that 3D digital breast tomosynthesis increased overall cancer detection by 28.6% and invasive cancer detection by 43.8%. The technology also reduced recall rates in community-based radiology practice.
Researchers at the University of Missouri have discovered a potential cholesterol-lowering drug that can also halt the progression of breast cancer and kill cancerous cells. The compound targets the production of cholesterol in cancer cells, leading to cell death.
A recent study found that most elderly women with non-metastatic breast cancer comply with hormone therapy recommendations. However, non-white women were more likely to discontinue treatment, highlighting a need for targeted interventions.
Researchers at Georgetown University Medical Center found that combining tamoxifen with hydroxychloroquine reverses resistance to the breast cancer drug in mice. The study's findings provide a promising new treatment option for women with advanced estrogen receptor-positive breast cancer.
A new study found that women with breast cancer who test positive for BRCA mutations are more likely to change their surgical plan, typically opting for a double mastectomy and sometimes ovary removal. Genetic testing before surgery can significantly impact treatment decisions, but may not necessarily delay surgery.
A class of leukemia drug has been found to stimulate immunity against multiple cancer types. Inhibiting the p110δ enzyme helps boost the body's immune system to kill tumor cells.
The Journal of Medical Imaging has launched with freely accessible articles on new research in cancer diagnosis, image quality assessment, and other topics. The journal covers fundamental and translational research in medical imaging, spanning physics, tomographic reconstruction algorithms, computer-aided diagnosis, and more.
Researchers found an association between decreased carbohydrate intake and reduced breast cancer recurrence among women whose tumor tissue is positive for the IGF-1 receptor. The study suggests that personalized diets based on molecular characteristics of primary tumors may be possible, but further research is needed.
A US-based study of 88,803 premenopausal women found a significant association between high red meat intake and increased breast cancer risk. Replacing red meat with a combination of legumes, poultry, nuts, and fish was linked to a lower risk of breast cancer.
Researchers analyzed the impact of mammography on breast cancer rates and found a significant decrease in late-stage diagnoses. The study attributed this decline to successful screening programs, which led to increased detection of early-stage cancers.
Two studies published in PLOS Medicine found a link between moles and increased breast cancer risk. Women with more moles were more likely to develop breast cancer, particularly postmenopausal women. The findings suggest that nevi may be affected by hormone levels, which could be used as a marker for breast cancer risk.
Researchers at MedStar Washington Hospital Center found that African-American women are more likely to be diagnosed with biologically less favorable subtypes of breast cancer. Genomic profiling identified specific molecular subtypes associated with a higher risk of recurrence.
Breast cancer patients often do not meet national physical activity guidelines after diagnosis, with African-American women being less likely to do so. A study found that only 35% of survivors met guidelines post-diagnosis, with a significant decrease in activity six months after diagnosis.
A new molecular breast imaging protocol using a higher dose of Tc-99m filtered sulfur colloid has been shown to improve the detection of advanced breast cancer. Imaging performed the day prior to surgery was more sensitive than imaging on the day of surgery, detecting 76% versus 49% of cases with metastasized lymph nodes.
A new antibody-based molecular imaging agent has been developed to target the HER3 receptor in breast cancer, which may lead to better diagnosis and treatment of high-risk cases. This approach could also help identify patients who would benefit from additional therapies.
A recent MSU study has discovered that many preclinical models of human breast cancer can replicate several key characteristics, particularly at the gene level. The researchers analyzed 1,172 mouse mammary tumor samples from 26 different models and found that most human breast cancers can be represented by one specific strain of mice.
As women age, their breast cells lose responsiveness to their surroundings, leading to increased tumor growth and higher risk of breast cancer. Researchers at Berkeley Lab discovered that multipotent progenitor cells, responsible for maintaining healthy tissue, fail to perceive differentiation cues as they age.
Researchers have identified four new genes that increase familial breast cancer risk, with RINT1 also linked to a broad spectrum of gastrointestinal and gynecological cancers. The study has significantly expanded the panel of genes known to account for increased breast cancer occurrence within families.
A Kaiser Permanente study published in the Journal of Clinical Oncology found that patients with small HER2+ breast cancer tumors (<0.5 cm) had a high survival rate without distant recurrence, even without treatment. For larger tumors (0.6-1 cm), the risk was slightly lower but still remained low.
The American Society of Clinical Oncology recognizes MD Anderson leaders Gabriel Hortobagyi, Waun Ki Hong, and John Mendelsohn for their significant contributions to cancer research. Mendelsohn is known for his discovery of the monoclonal antibody Erbitux, while Hong has made groundbreaking advances in treating head and neck cancers.
Scientists identified a new protein, hnRNPM, that plays a key role in reprogramming breast cancer cells to spread. Removing this protein significantly reduces the ability of breast cancer cells to metastasize to other organs.
The ALTTO trial showed that adding lapatinib to trastuzumab and chemotherapy did not improve patient outcome, while increasing toxicity. Researchers suggest standard adjuvant treatment should remain trastuzumab with chemotherapy for early stage HER2-positive breast cancer.
The number of cancer survivors in the US is expected to grow from 14.5 million to almost 19 million by 2024 due to an aging population and improved treatment outcomes. The majority of cancer survivors were diagnosed five or more years prior, with nearly half aged 70 or older.
Four phase III trials released findings on new chemotherapy regimens and targeted treatments for advanced cancers. The studies confirm the effectiveness of commonly used treatments and provide insights into optimal patient care.
Research identifies new ways to ease cancer therapy effects and enhance patient well-being, from fertility preservation techniques to earlier palliative care. Studies show improved survival rates and reduced side effects for certain treatments.
Researchers found that reducing the frequency of bisphosphonate treatment from monthly to every three months after one year was non-inferior to continuing monthly treatment in terms of efficacy. The study also showed a reduced risk of serious side effects, including kidney-related adverse events.
A new clinical trial found that adding goserelin to chemotherapy regimens for premenopausal women with early-stage breast cancer significantly reduced the risk of early menopause. The study also showed improved overall survival rates and a higher pregnancy rate in the goserelin group.
Myriad Genetics Inc. presented new data on its BRACAnalysis CDx and HRD tests, supporting their clinical efficacy in predicting platinum-based therapy response for triple negative breast cancer patients. The company also announced an early access launch of the HRD test in FY15.
The investigational agent DMOT4039A, a combination of chemotherapeutic agent and antibody, showed initial evidence of anti-cancer activity in a phase I clinical trial for pancreatic and ovarian cancers. The drug targets mesothelin-rich cancer cells, reducing the risk of off-target effects.